Immunotherapy inches forward in head and neck cancer trials
Cancer Center expert featured in Targeted Therapies in Oncology article
The University of Cincinnati Cancer Center's Trisha Wise-Draper was featured in a Targeted Therapies in Oncology article discussing the current state and future of immunotherapy trials to treat head and neck cancer.
Immunotherapy treatments use the body's own immune system to target cancer cells and have become an important option for many types of cancer. But there is more to learn on the best uses of immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC).
“Outside of the recurrent and metastatic setting, where we have clear indications about when to give immunotherapy, I think it’s still too early to give it in the definitive setting,” said Wise-Draper, MD, PhD, a Cancer Center physician researcher, professor of medicine in the Division of Hematology/Oncology, section head of medical oncology, co-leader of the Head and neck Experimental Advancement Laboratory in UC's College of Medicine and deputy director of UC's Office of Clinical Research.
“I’d wait until we have a little bit more information, especially with giving immunotherapy before surgery, until we have the results from the clinical trial.”
Read the Targeted Therapies in Oncology article.
Featured photo at top of Wise-Draper, left, and Vinita Takiar in the Head and neck Experimental Advancement Laboratory. Photo/Colleen Kelley/UC Marketing + Brand.
Related Stories
Children exposed to gambling mechanics before they understand money
February 4, 2026
Gambling-style mechanics are becoming a routine part of children’s digital lives, appearing in online games, mobile apps and even sports betting advertisements that surround popular media. University of Cincinnati experts warned in a recent WKRC-TV Local 12 report that long before children understand the value of money, they are learning the emotional highs and lows associated with risk. Online games, such as Roblox and Fortnite, offer fast-paced rewards that can keep children glued to screens.
Study: Synthetic protein potentially improves outcomes for certain subgroups following intracerebral hemorrhage
February 4, 2026
The University of Cincinnati’s Joseph Broderick, MD, presented results from the FASTEST trial at the International Stroke Conference, simultaneously published in The Lancet, that found administering a synthetic protein, recombinant Factor VIIa, can reduce bleeding and potentially improve outcomes for certain patients at the highest risk of continued bleeding following an intracerebral hemorrhage.
UC expert explains 25th Amendment
February 4, 2026
WVXU's Cincinnati Edition talks to a University of Cincinnati political science professor about the 25th Amendment to the U.S. Constitution.